Harbourvest Partners’s Pliant Therapeutics PLRX Stock Holding History

Harbourvest Partners’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-49,434	Closed	-$554K	–	33
2024 Q3	$554K	Hold	49,434	–	–	0.29%	23
2024 Q2	$531K	Hold	49,434	–	–	0.28%	26
2024 Q1	$737K	Hold	49,434	–	–	0.34%	31
2023 Q4	$895K	Hold	49,434	–	–	0.3%	33
2023 Q3	$857K	Hold	49,434	–	–	0.29%	34
2023 Q2	$896K	Buy	+49,434	New	+$1.17M	0.25%	38
2022 Q4	–	Sell	-64,826	Closed	-$1.35M	–	68
2022 Q3	$1.35M	Buy	+64,826	New	+$1.24M	0.44%	29

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Harbourvest Partners's PLRX Position: Q4 2024 in Review

Harbourvest Partners sold out of Pliant Therapeutics (PLRX) in Q4 2024, closing a stake of 49,434 shares — an estimated $554K sold.

Harbourvest Partners first reported a position in PLRX in Q3 2022 and held it in 7 quarters. The position peaked at $1.35M in Q3 2022. 160 funds tracked by Wall St. Rank hold PLRX as of Q4 2024.

Harbourvest Partners reported no remaining Pliant Therapeutics position as of Q4 2024 after selling out during the quarter.
Harbourvest Partners sold 49,434 Pliant Therapeutics shares in Q4 2024, an estimated $554K.
Harbourvest Partners first reported a position in Pliant Therapeutics in Q3 2022 and held it in 7 quarters.
Harbourvest Partners's Pliant Therapeutics position peaked at $1.35M in Q3 2022.
160 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2024.

Based on Harbourvest Partners's 13F filing for Q4 2024, filed 14 Feb 2025.